Mukaide Motokazu, Sugiyama Masaya, Korenaga Masaaki, Murata Kazumoto, Kanto Tatsuya, Masaki Naohiko, Mizokami Masashi
Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, 1-7-1 Kohonodi, Ichikawa, Chiba 272-8516 Japan; Research and development department, SRL, Inc., 5-6-50 Shin, Hino, Tokyo 191-0002, Japan.
Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, 1-7-1 Kohonodi, Ichikawa, Chiba 272-8516 Japan.
J Virol Methods. 2014 Oct;207:169-77. doi: 10.1016/j.jviromet.2014.07.006. Epub 2014 Jul 11.
The next-generation droplet digital polymerase chain reaction (ddPCR) assay employs an emulsion-based endpoint to quantitate the amount of target DNA and is more robust than real-time PCR when analyzing sequence variations. However, no studies have applied this technique to quantitate mutations in polymorphic viral genomes. To develop this approach, a ddPCR-based assay was designed to quantitate with high-throughput and sensitivity mutations and their frequencies in codon 70 of the hepatitis C virus (HCV) gene that encodes the Core protein. The assay was linear from 2.5 to 10(5) copies per assay, and the limit of detection of mutants in the presence of a 20,000-fold excess of wild type was 0.005%. The results correlated well with those obtained using the COBAS(®) TaqMan(®) HCV Test, which is a real-time PCR assay for the quantitative detection of HCV RNA in human serum (n=87; range, 2.3-7.7log10IU/mL; Pearson's R(2)=0.9120; p<0.0001). The median frequencies of mutations by ddPCR were 0.262% (n=55; range, 0-37.951%) and 99.687% (n=32; range, 52.191-100%) for the wild-type and mutant sequences, respectively, by direct sequencing. The ddPCR assay should be useful for quantitating mutations in other polymorphic viral genomes.
下一代液滴数字聚合酶链反应(ddPCR)检测采用基于乳液的终点法来定量目标DNA的量,并且在分析序列变异时比实时PCR更稳健。然而,尚无研究将该技术应用于定量多态性病毒基因组中的突变。为了开发这种方法,设计了一种基于ddPCR的检测方法,用于高通量且灵敏地定量丙型肝炎病毒(HCV)编码核心蛋白的基因第70位密码子中的突变及其频率。该检测方法在每次检测2.5至10⁵个拷贝时呈线性,在野生型过量20000倍的情况下,突变体的检测限为0.005%。结果与使用COBAS® TaqMan® HCV检测法获得的结果高度相关,COBAS® TaqMan® HCV检测法是一种用于定量检测人血清中HCV RNA的实时PCR检测法(n = 87;范围,2.3 - 7.7log₁₀IU/mL;Pearson相关系数R² = 0.9120;p < 0.0001)。通过直接测序,ddPCR检测到的野生型和突变型序列的突变频率中位数分别为0.262%(n = 55;范围,0 - 37.951%)和99.687%(n = 32;范围,52.191 - 100%)。ddPCR检测法应有助于定量其他多态性病毒基因组中的突变。